Numab Therapeutics raises €20.3M Series B round
9 March 2020· Horgen, Switzerland· health, biotech, immunotherapy, drug_discovery, b2b
The funds will be used to expand Numab's proprietary pipeline of differentiated multispecific therapeutics for cancer and to support the advancement of its lead oncology program ND021 into clinical testing.
About Numab Therapeutics
Stage
Series C
Headquarters
Horgen, Switzerland
Founded
2011
Team Size
51–200
Sectors
healthbiotechimmunotherapydrug_discoveryb2b